Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress
03 November 2017 - 7:52AM
Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a pharmaceutical company
developing novel therapeutic products that modulate the human gut
microbiome to treat gastrointestinal diseases, today announced that
the Company’s Chief Executive Officer, Michael Step, will present
at the 5th Microbiome R&D Business Collaboration Forum / 2nd
Annual Probiotic Congress on November 3, 2017, in San Diego. Mr.
Step presentation is entitled: “Pioneering Development in the Gut
Microbiome for the Treatment of Lactose Intolerance.”
About Ritter
Pharmaceuticals
Ritter Pharmaceuticals, Inc.
(www.RitterPharma.com, @RitterPharma) develops novel therapeutic
products that modulate the gut microbiome to treat gastrointestinal
diseases. Its lead product, RP-G28, has the potential to become the
first FDA-approved treatment for lactose intolerance, a condition
that affects millions worldwide. The Company is further exploring
the functionality and discovering the therapeutic potential gut
microbiome changes may have on treating/preventing a variety of
conditions including: gastrointestinal diseases, immuno-oncology,
metabolic, and liver disease.
Forward-Looking Statements
This release may contain forward-looking
statements, which express the current beliefs and expectations of
Ritter Pharmaceuticals’ management. Such statements involve a
number of known and unknown risks and uncertainties that could
cause the Company’s future results, performance or achievements to
differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Any
statements contained herein that do not describe historical facts
are forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from those
discussed in such forward-looking statements. These forward-looking
statements are made only as of the date hereof, and the Company
undertakes no obligation to update or revise the forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts
Investor Contact:
Jeffrey Benjamin
310-203-1000
jeffrey@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Apr 2024 to May 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Ritter Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles